Custirsen as Treatment for Prostate Cancer

April 10, 2014
Oliver Sartor, MD

Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses a phase III trial of custirsen (OGX-011) and its potential for treatment in patients with prostate cancer.

Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses a phase III trial of custirsen (OGX-011) and its potential for treatment in patients with prostate cancer.

Clinical Pearls:

  • A phase III trial of custirsen in combination with docetaxel has been conducted and results are expected to be available within a year
  • Based on a phase II trial, the combination appeared to be more effective than docetaxel when used as mono therapy
  • This phase III trial will determine if custirsen plus docetaxel is more effective than docetaxel alone for patients with castration-resistant prostate cancer